BETA
Your AI-Trained Oncology Knowledge Connection!
Jordyn Sava is an editor for Targeted Oncology.
ASCO 2025 Briefing: Advances in Breast, Lung, and Obesity-Linked Cancers
The ASCO 2025 press briefing showcased early highlights in cancer therapy. Here’s what you need to know.
Neel Shah: "The Community Setting Is Where the Patients Are"
Neel Shah, MD, our first 2025 Oncology Icon, reflected on his journey from academic medicine to community oncology.
National Cancer Research Month: A Look at Progress and Future Directions
Manmeet Ahluwalia, MD, MBA, FASCO, discussed the significance of National Cancer Research Month and highlighted how ongoing cancer research directly impacts patient care.
Phase 1 GTB-3650 Trial Advances for CD33+ Malignancies
Cohort 1 of the GTB-3650 phase 1 trial completed with no safety issues observed in patients with CD33-expressing hematologic malignancies.
Understanding Patient Distress via EHR in Community Oncology
Kat M. Aguilar, MPH, discussed the findings of the recent study evaluating the early adoption of the distress thermometer.
ODAC Rejects Label Expansion for Talazoparib in Non-HRRm mCRPC
The ODAC deemed the results from TALAPRO-2 are not sufficient to conclude a favorable benefit-risk profile for adding talazoparib to enzalutamide in non-HRRm mCRPC.
Biomarker Testing Expands in Metastatic Bladder Cancer
Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.
FDA ODAC Votes 5 to 4 Against UGN-102 for Recurrent LG-IR-NMIBC
The FDA ODAC decided that the overall benefit-risk of the investigational therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk NMIBC.
Hope on the Horizon: Brain Cancer Advances in Awareness Month
Manmeet Ahluwalia, MD, MBA, FASCO, discussed the importance of Brain Cancer Awareness Month for a community oncologist audience.
FDA Oks Phase 3 Trial of PT-112 in mCRPC Following Successful EOP2 Meeting
PT-112 monotherapy advances to phase 3 trial in metastatic castration-resistant prostate cancer after positive FDA end of phase 2 meeting.
AI Predicts Prostate Cancer Prognosis Fairly Across Races
Mack Roach III, MD, discussed a study on artificial intelligence’s generalizability for prostate cancer across racial groups.
Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Myeloma
Ashraf Z. Badros, MBChB, discussed the results from the AURIGA trial of maintenance therapy with daratumumab and lenalidomide in newly diagnosed multiple myeloma.
Advancements in EGFR+ NSCLC Treatment: MARIPOSA and COCOON
Nicolas Girard, MD, PhD, discussed findings from the MARIPOSA and COCOON trials of amivantamab and lazertinib in EGFR+ NSCLC.
Phase 1 Trial of mRNA-4106 Begins Dosing Patients With Solid Tumors
A phase 1 trial of mRNA-4106 has dosed its first patient with an advanced or metastatic solid tumor.
The Targeted Pulse: FDA Approvals in Ovarian Cancer, Lung Cancer, and More
The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.
Melphalan/HDS Shows Benefit in Metastatic Uveal Melanoma
Melphalan/hepatic delivery system showed better survival and response rates than best alternative care in metastatic uveal melanoma in the FOCUS trial.
Melanoma Awareness Month: Pecora’s Insights on Prevention and Treatment
In an interview for Melanoma Awareness Month, Andrew Pecora, MD, discussed melanoma prevention and treatment for fellow oncologists.
Samuraciclib Shows PFS Benefit in Biomarker-Selected HR+ Breast Cancer
Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver metastases.
Belrestotug Program Terminated After Mixed Phase 2 Results in NSCLC
Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all development and ongoing trials.
FDA Grants Telisotuzumab Vedotin Accelerated Approval in c-MET+ NSCLC
The FDA granted accelerated approval to telisotuzumab vedotin for the treatment of NSCLC with high c-MET protein overexpression.
FDA Approves Belzutifan in Advanced Pheochromocytoma and Paraganglioma
The FDA approved belzutifan as the first oral therapy for advanced or metastatic pheochromocytoma and paraganglioma in patients 12 years and older.
BOND/CORE-001: uGDB as a Biomarker for Viral Therapy in Bladder Cancer
Colin P.N. Dinney, MD, PhD, discussed updated analyses of the BOND-003 and CORE-001 trials in bladder cancer.
First-Line Disitamab Vedotin/Toripalimab Shows Benefit in HER2+ la/mUC
Disitamab vedotin plus toripalimab showed significant survival benefits vs chemo in first-line HER2+ advanced urothelial carcinoma, with a manageable safety profile.
Durvalumab Plus BCG Improves Survival in Early Bladder Cancer
Durvalumab plus full BCG significantly improved disease-free survival in high-risk early bladder cancer vs BCG alone in the POTOMAC trial.
Avutometinib Plus Defactinib Gains FDA Approval in KRAS+ Ovarian Cancer
Avutometinib given with defactinib is now approved for the treatment of adult patients with recurrent low-grade serous, KRAS-positive ovarian cancer.
FDA Fast-Tracks Givinostat for Polycythemia Vera Treatment
The FDA granted fast track status to givinostat for treating high-risk polycythemia vera, supporting its potential shown in the ongoing phase 3 GIV-IN PV trial.
Elraglusib Combo Improves Survival in First-Line mPDAC
Improved Outcomes With Transplant After Cladribine-Based Therapy in AML
Transplantation improves survival after cladribine-based therapy for patients with relapsed/refractory acute myeloid leukemia, per phase 2 trial findings.
IFx-Hu2.0 Enters Clinical Trials for Merkel Cell Carcinoma
Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.
FDA Issues Refusal to File for Nogapendekin Alfa Plus BCG in Papillary NMIBC
The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior positive feedback.